Overpatented, Overpriced: Special Humira Edition
Treatment advocate tactics to expand access to antiviral therapy for HIV and viral hepatitis C in low- to high-income settings: making sure no one is left behind
Worldwide, 71 million people are infected with hepatitis C virus (HCV), which, without treatment, can lead to liver failure or hepatocellular carcinoma. HCV co-infection increases liver- and AIDS-related morbidity and mortality among HIV-positive people, despite ART. A 12-week course of HCV direct-acting antivirals (DAAs) usually cures HCV – regardless of HIV status. However, patents and…
The critical role of civil society in shaping the market for antiretroviral therapy and direct-acting antivirals
Civil society – in particular people living with and affected by HIV/AIDS – helped shape the market for antiretroviral drugs in low- and middle-income countries. There is a critical need to support civil society interventions that will similarly impact treatment access for hepatitis C.
The HIV Drug Pipeline and its Patents
The Roadmap is intended to help expand access to the next generation of life-saving ARVs in multiple ways. The pages that follow summarize clinical, cost, and legal/patent information around key pipeline drugs for HIV/AIDS.
Patent Landscape Report For Pegylated Interferon Alfa 2A & 2B
Evaluating The Potential Impact Of Aurobindo’s Unbundling
Examination of the potential benefit, if any, of Aurobindo’s decision to opt out of the MPP-Gilead license for TDF.
Financial Impact Of The Medicines Patent Pool: I-MAK/ITPC Counter Analysis
We prepared the following analysis as a response to claims made by the MPP about its economic benefits.
Measuring the Impact of Medicines Patent Pool Licenses: A Civil Society Assessment
Why UNITAID Matters for People Living with HIV/AIDS, TB and Malaria – Market Impact Report by the Civil Society Delegations Civil Society Assessment Presentation
HIV Drug Patents in China – A Patent Landscape
This report focuses on the HIV drug patent landscape in China. The patents included this landscape include key ARV patents that are likely to have a bearing on procurement decisions in China.
India and Second-Line ART, Evaluating the Way Forward, INP+ Discussion Paper
This discussion paper was commissioned by the Indian Network for People Living with HIV/AIDS (INP+) to address the feasibility of introducing second-line ART into NACO’s public-sector treatment programme.